As newer classes of targeted therapies are developed, such as KRAS, P53, PI3K and EGFR inhibitors53, and more anti-lung cancer drugs are developed to specific genetic targets, it is important to develop immunocompetent mouse models capable of responding to treatments. This evidence concerns the gene KRAS and lung cancer.